Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.79%
As of Monday, August 17, Adicet Bio, Inc.’s ACET share price has surged by 5.79%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 14.08%
As of Thursday, August 06, Adicet Bio, Inc.’s ACET share price has dipped by 14.08%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 13.10%
As of Thursday, August 06, Adicet Bio, Inc.’s ACET share price has dipped by 13.10%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 5.68%
As of Friday, July 31, Adicet Bio, Inc.’s ACET share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.66%
As of Thursday, July 30, Adicet Bio, Inc.’s ACET share price has surged by 5.66%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ACET | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $101.0 | $286.3 | 21% |
|
| Shares Out (Mil) | 10.7 | 54.2 | 21% |
|
| Institutional Ownership | 98.0% | 92.8% | 77% |
|
| Float (Mil) | 7.4 | 39.7 | 16% |
|
| Beta | 1.59 | 0.94 | 85% |
|
| Avg Daily Volume (000s) | 72 | 534 | 31% |
|
| Price Change (52-week) |
(10.9%) | 58.7% | 36% |
|
| Growth | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (26.1%) | (10.1%) | 16% |
|
| EPS (5yr) | 26.7% | 16.0% | 77 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.6%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($1.640) | ($6.396) | ($3.950) | |
| Month Ago EPS | ($1.510) | ($8.868) | ($4.192) | |
| # Rev Up | 2 | 2 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($1.510) | ($8.868) | ($4.192) | |
| Year/Year Chg | (17.5%) | (62.3%) | (100.7%) | |
| Financials | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($99) | ($43) | 11% |
|
| EPS (TTM) | ($10.519) | ($1.400) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($85) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $2 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | ($18) | $160 | 1% |
|
| Valuation | ACET | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.84 | 2.77 | 16% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ACET | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (63.6%) | (47.3%) | 9% |
|
| ROE | (78.1%) | (55.0%) | 11% |
|
| Liabilities to Assets | 18.9% | 29.6% | 12% |
|
| F-Score | 1 | 2 | 1% |
|
Adicet Bio, Inc. did not pass any screens on 8/20/2026.
